|| List of recent Polyp-related patents
|Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Polynucleotides and polypeptides in plants|
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed..
|Compositions and methods for altering alpha- and beta-tocotrienol content|
Preparation and use of isolated nucleic acids useful in altering the oil phenotype in plants. Isolated nucleic acids and their encoded polypeptides that alter alpha- and beta-tocotrienol content in seeds and oil obtained from the seeds.
|Polynucleotides and polypeptides that confer increased yield, size or biomass|
The present description relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant, including the traits of increased yield, size or biomass.. .
|Polyphenylene ether-based resin composition and method for producing the same|
To provide a resin composition that has a high impact resistance, hardly causes peeling during molding, and is excellent in flame retardancy, heat resistance, and heat aging resistance for a long period. A resin composition containing (a) polyphenylene ether, (b) a hydrogenated block copolymer that is obtained by hydrogenating a block copolymer including a polystyrene block and a conjugated diene compound polymer block, and that has a weight average molecular weight of 100,000 to 500,000, and (c) an organic phosphorus-based flame retardant within a specified amount, wherein a value of the loss tangent (tan δ) peak height of the (b) component in a dynamic viscoelasticity spectrum obtained by measurement of the resin composition at a frequency of 10 hz is in a specified range..
|Flame-retardant agent and flame-retardant resin composition|
The present invention provides a composite flame retardant which can be produced without using any toxic metal such as antimony trioxide or any halogen such as bromine and chlorine and can exhibit excellent flame retardancy compared with magnesium hydroxide when added in a smaller amount; and a flame retardant resin composition having excellent flame retardancy and excellent physical properties. The present invention relates to a flame retardant including: (a) 100 parts by mass of a reaction product of piperazine with one phosphorus compound selected from phosphoric acid, pyrophosphoric acid, and polyphosphoric acid; (b) 10 to 1000 parts by mass of a reaction product of melamine with a polyacid selected from cyanuric acid, phosphoric acid, pyrophosphoric acid, and polyphosphoric acid; and (c) 0.1 to 100 parts by mass of a reaction product of calcium or magnesium with silicic acid..
|Modified polynucleotides for treating carboxypeptidase n, polypeptide 1 protein deficiency|
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmrna molecules.. .
|Wnt compositions and methods of use thereof|
Wnt compositions and methods for their use are provided. Compositions of the invention comprise fragments of wnt polypeptides having a desired biological activity, which fragments are referred to herein as “mini-wnts”.
|Immunotherapeutic methods using epitopes of wt-1 and gata-1|
A peptide comprising the amino acid sequence rmfpnapyl or a portion or variant thereof provided that the peptide is not intact human wt-1 polypeptide or a peptide comprising the amino acid sequence cmtwnqmnl or a portion or variant thereof provided that the peptide is not intact human wt-1 polypeptide or a peptide comprising the amino acid sequence hlmpfpgpll or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines..
A method for releasing the content of the periplasmic space of bacterial cells is provided, which comprises incubating the bacterial cells in a solution containing styrene maleic acid copolymer (sma). Also provided is a method of preparing a substantially pure sample of recombinant polypeptide.
|Glucanases, nucleic acids encoding them and methods for making and using them|
The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-d-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-d-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-d-glucans or xyloglucans and other plant material containing cellulosic parts.
|Influenza b viruses having alterations in the hemaglutinin polypeptide|
The present invention encompasses methods of producing influenza b viruses in cell culture. The influenza b viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza b virus infection..
|Method for producing a soluble cocoa product from cocoa powder|
The present invention relates to a method for producing a soluble cocoa product from cocoa powder. The present invention further relates to cocoa products obtained by the present method and uses thereof.
|Edible brown algae extract with a low iodine content|
The invention relates to a brown algae extract containing less than 50 ppm of iodine and between 5 and 15%, and preferably between 8 and 10%, of polyphenols, said percentage of polyphenols being expressed as a chlorogenic acid equivalent in relation to the dry weight of the extract, the invention also relating to an oral absorption composition comprising such an extract, and to a method for preparing the extract according to the invention.. .
|Novel polypeptides and use thereof|
The present invention provides a polypeptides capable of modulating tissue transglutarmnase-induced cell behaviour wherein the polypeptide comprises or consists of either (a) the amino acid sequence of a heparin-binding site of a tissue transglutaminase, or a functional fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof or (b) an antibody capable of binding to a heparin-binding site of a lissue transglutaminase, or an antigen-binding fragment or derivative thereof. In one embodiment, the heparin-binding site of a tissue transglutaminase comprises or consists of an amino acid sequence of seq id no: 1, the invention further provides medical uses of the polypeptides of the invention and methods of treatment using the same..
|Stabilizing polypeptides which have been exposed to urea|
Methods for stabilizing polypeptides, such as anti-her2 antibodies, which have been exposed to urea.. .
|Modulators of the nlrp3 inflammasome il-1beta pathway for the prevention and treatment of acne|
The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of il-1β, il-1 receptor type 1, nlrp3, asc, caspase-1 and cathepsin b with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of il-1β, il-1 receptor type 1, il-1 receptor type 2, nlrp3, asc and caspase-1. Similarly, an interfering rna or an antisense modulator of gene expression of il-1β, i l-1β receptor type 1, nlrp3, asc, caspase-1 and cathepsin b are provided for the prevention or treatment of acne..
|Process for the production of fine chemicals|
The present invention relates to a process for the production of the fine chemical in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof, preferably in plastids. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antibodies, host cells, plant tissue, propagation material, harvested material, plants, microorganisms as well as agricultural compositions and to their use..
|Compositions comprising agents that inhibit neuropilin and tolloid like 2|
We disclose agents that inhibit the expression of neto-2 which has elevated expression in cancer stem cells; the use of neto-2 as a diagnostic or prognostic marker of tumour initiation; the use neto-2 polypeptides in the identification of agents that inhibit activity; and including antibodies that bind neto-2 and vaccines comprising neto-2 polypeptides.. .
The present inventors produced a heterodimerized polypeptide having an fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an fc region with improved fc region function compared to that of a homodimer in which the fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.. .
|Structural mutations in titin cause dilated cardiomyopathy|
Provided herein are diagnostic markers and methods for identifying a subject having an increased susceptibility for developing or having dilated cardiomyopathy. The method comprises determining if the subject has a mutation in the ttn nucleic as acid or titin polypeptide.
|Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof|
Provided are soluble neutral active hyaluronidase glycoproteins (shasegp's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
|Composition for reducing toilet odor containing polypropylene glycol as a reactive gas barrier|
A method and composition is provided that aids in the reduction of objectionable volatile odors when a few drops are placed in the toilet prior to use. In one embodiment, the composition contains a high molecular weight polypropylene glycol (ppg) together with a dispersing agent to create an instantaneous multifunctional surface barrier of the polypropylene glycol/isopropanol mixture across the water surface.
|Urea filter material|
A urea filter material may have a base layer, a cover layer and a filter layer arranged between the base layer and the cover layer, wherein all of the layers are formed from polypropylene non-woven fabric.. .
|Axmi221z, axmi222z, axmi223z, axmi224z and axmi225z delta-endotoxin genes and methods for their use|
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
|Plants having altered agronomic characteristics under nitrogen limiting conditions and related constructs and methods involving genes encoding lnt6 polypeptides and homologs thereof|
Isolated polynucleotides and polypeptides and recombinant dna constructs particularly useful for altering agronomic characteristics of plants under nitrogen limiting conditions, compositions (such as plants or seeds) comprising these recombinant dna constructs, and methods utilizing these recombinant dna constructs. The recombinant dna construct comprises a polynucleotide operably linked to a promoter functional in a plant, wherein said polynucleotide encodes an lnt6 polypeptide or homolog thereof..
|Plant transcriptional regulators|
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having improved tolerance to drought, shade, and low nitrogen conditions, as compared to wild-type or reference plants.. .
|Ultrasound based method and apparatus to determine the size of kidney stone fragments before removal via ureteroscopy|
A transducer is used to send an ultrasound pulse toward a stone and to receive ultrasound reflections from the stone. The recorded time between a pulse that is reflected from the proximal surface and a pulse that is reflected either from the distal surface of the stone or from a surface supporting the stone is used to calculate the stone size.
|B7-related nucleic acids and polypeptides useful for immunomodulation|
The present invention provides nucleic acids encoding b7-related factors that modulate the activation of immune or inflammatory response cells, such as t-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding b7-related polypeptides, including bsl1, bsl2, and bsl3.
|Modified chimeric polypeptides with improved pharmacokinetic properties|
The present invention provides vegf antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing vegf activity is provided comprising a modified extracellular ligand binding domain of a vegf receptor fused to a multimerizing component..
|Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use|
The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight.
|Blends of polysulfones and polyphenylene sulfide resins|
Various embodiments relate to a method of compatibilizing a blend of polysulfone (psu) and polyphenylene sulfide (pps). The method can include a) melt mixing a polysulfone (psu) and a polyetherimide; and b) melt mixing a polyphenylene sulfide (pps) and an epoxy.
|Blends of polyethersulfones and polyphenylene sulfide resins|
A composition including a blend of: a) a polyethersulfone; b) a polyphenylene sulfide (pps); and c) an epoxy, and optionally a polyetherimide, wherein the polyetherimide and epoxy are present in an amount effective to act as a compatibilizer for the polyethersulfone and polyphenylene sulfide (pps). Methods of compatibilizing a blend of polyethersulfone and polyphenylene sulfide (pps).
|Propylene impact copolymers having good optical properties|
Propylene impact copolymers (icps) are provided which comprise: (a) a matrix phase which comprises from 60 to 95 weight % of a polypropylene polymer containing from 0 to 6 mole % of units derived from one or more alpha-olefins other than propylene, and (b) a dispersed phase which comprises from 5 to 40 weight % of a copolymer derived from a first comonomer which can be either propylene or ethylene together with a second alpha-olefin comonomer. The icp is further characterized by having a beta/alpha ratio less than or equal to 1.1.
|Blends of polyphenylene sulfones and polyphenylene sulfide resins|
Blends of a polyphenylene sulfone (ppsu); a polyphenylene sulfide (pps); and, a polyetherimide and epoxy. The polyetherimide and epoxy are present in an amount effective to act as a compatibilizer for the polyphenylene sulfone (ppsu) and polyphenylene sulfide (pps).
|Polyprenylated benzoylphloroglucinols with anticancer activity|
Two novel polyprenylated benzoylphloroglucinol derivatives, garciesculentones a and c, are disclosed in the present invention. Garciesculentones a and c exhibit cytotoxicity and/or antimigration effect against various cancer cell lines.
|Sequence-specific inhibition of small rna function|
The present invention relates to the discovery of a method for inhibiting rna silencing in a target sequence-specific manner. Rna silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide.
|Use of endostatin peptides for the treatment of fibrosis|
C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed.
|Modified relaxin polypeptides and their uses|
Modified relaxin polypeptides and their uses thereof are provided. .
|Isolated nucleic acid molecules encoding variant activin receptor polypeptides|
The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
|Methods for treatment of nephrotic syndrome and related conditions|
The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein.
|Fusion peptide designed to reduce plaque bacteria and yeast in the oral cavity|
The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to lactoferrin and pak fusion peptides (pak-lf), along with therapeutic, diagnostic and research uses for these polypeptides.